




Certificate of Mailing (37 C.F.R. §1.8):  
I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to:  
Commissioner for Patents,  
PO Box 1450, Alexandria, VA 22313-1450  
on this 6th day of November 2003.

s/   
Julie Agozino

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re the Application of:  
**LYN HOWARD JONES, ET. AL.**

Serial No.: 10/669,794

Confirmation No.: TBA

Filed: September 23, 2003

For: PYRAZOLE DERIVATIVES

Group Art Unit: TBA

Examiner: TBA

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(b)**

Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 CFR 1.56, Applicant brings the documents listed on the attached substitute Form PTO-1449 to the attention of the Examiner for consideration in connection with the examination of the above-identified application.

This Information Disclosure Statement is being filed within the period specified in 37 CFR 1.97(b)-i.e., (1) within three months of the filing date of the national application, (2) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application, or (3) to the undersigned's knowledge, before the mailing date of a first Office Action on the merits, whichever event occurs last.

It is respectfully requested that the Examiner confirm consideration of the cited documents by initialing the attached substitute Form PTO-1449 and returning a copy of the initialed form to the Applicant.

If any fees are due in connection with the filing of this statement, including the fee set forth in 37 CFR 1.17(p) in the event that the period specified in 37 CFR 1.97(b) has elapsed, please charge all required fees to Deposit Account No. 500329.

Respectfully submitted,

Date: Nov. 5, 2003

Keith D. Hutchinson  
Keith D. Hutchinson  
Attorney For Applicant  
Registration No. 43,687

Agouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 526-4608  
Fax: (858) 678-8233

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO



# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

## Complete if Known

Application Number	10/669,794
Filing Date	September 23, 2003
First Named Inventor	Lyn Howard Jones
Art Unit	To Be Announced
Examiner Name	To Be Announced
Attorney Docket Number	PC25376A

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. <sup>1</sup>	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup>			
	AA	3,303,200	02/07/1967	American Home Products Corporation	
	AB	5,037,834	08/06/1991	Pfizer, Inc.	
	AC	60/433,220		Pfizer, Inc.	

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	AD	WO 97/23462 ✓	07/03/1997	Pfizer Limited		
	AE	WO 98/30560 ✓	07/16/1998	Pfizer Limited		
	AF	WO 02/04424 ✓	01/17/2002	Pfizer Limited		
	AG	WO 02/30907 ✓	04/18/2002	F. Hoffmann-La Roche AG		
	AH	GB 0223357.8 ✓	09/26/2002	Pfizer Limited		
	AI	GB 0223357.5 ✓	10/08/2002	Pfizer Limited		

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

## Complete if Known

Application Number	10/669,794
Filing Date	September 23, 2003
First Named Inventor	Lyn Howard Jones
Art Unit	To Be Announced
Examiner Name	To Be Announced
Attorney Docket Number	PC25376A

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AJ	BERGE, et. al., "Pharmaceutical Salts," <i>Journal of Pharmaceutical Sciences</i> , 1977, 1-19, Vol. 66, No. 1.	
	AK	BIGHLEY, et. al., "Salt Forms of Drugs and Absorption," <i>Encyclopedia of Pharmaceutical Technology</i> , Marcel Dekker Inc., 1996, 453-497, Vol 13, New York.	
	AL	BUNGAARD, et. al., <i>Design of Prodrugs</i> , 1985, Chapter 1, Elsevier Science Publishers, Amsterdam, New York, Oxford.	
	AM	CAREY, et. al., "Structure and Mechanisms," <i>Advanced Organic Chemistry</i> , 3 <sup>rd</sup> Edition, Plenum Press, New York and London.	
	AN	FERRES, ET AL., "Pro-Drugs of $\beta$ -Lactam Antibiotics," <i>Drugs of Today</i> , 1983, 499-538, Vol. 19, No. 9.	
	AO	GENIN, et. al., "Novel 1,5-Diphenylpyrazole Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors with Enhanced Activity Versus the Delavirdine-Resistant P236L Mutant: Lead Identification and SAR of 3- and 4-Substituted Derivatives," <i>Journal of Medicinal Chemistry</i> , 2000, 1034-1040, Vol. 43, No. 5	
	AP	GREENE, et. al., <i>Protective Groups in Organic Synthesis</i> , 1991, Second Edition, John Wiley & Sons, New York, Chichester, Brisbane, Toronto, Singapore.	
	AQ	HABERMEHL, et. al., "The Condensation of Histamine with Carbonyl Compounds," <i>Heterocycles</i> , 1976, 127, Vol. 5, No. 1.	
	AR	KATRITZKY, et. al., "The Structure, Reactions, Synthesis and Uses of Heterocyclic Compounds," <i>Comprehensive Heterocyclic Chemistry</i> , 1984, Vol. 1-11, Pergamon Press, Oxford, New York, Toronto, Sydney, Paris, Frankfurt.	
	AS	Topics in Chemistry, 306-316, (Not Available)	

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.